- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| ZEO SCIENTIFIX Aktie jetzt für 0€ handeln | |||||
| 09.07. | Zeo ScientifiX, Inc.: ZEO ScientifiX Positions for National Growth as Stem Cell Market Opens in Florida | 372 | ACCESS Newswire | ZEO Launches New Website and Agency Partnerships to Address Expected Biologics Market Demand Following Florida's New Stem Cell Law FORT LAUDERDALE, FL / ACCESS Newswire / July 9, 2025 / ZEO ScientifiX... ► Artikel lesen | |
| 24.06. | Zeo ScientifiX, Inc.: ZEO ScientifiX Launches Physician-Focused Masterclass Ahead of Florida's SB-1768 Law Implementation | 186 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / June 24, 2025 / ?ZEO ScientifiX, Inc.?("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company pioneering the research and development... ► Artikel lesen | |
| 24.06. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.06. | Zeo ScientifiX, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 16.05. | Zeo ScientifiX, Inc. - S-1/A, General form for registration of securities | 3 | SEC Filings | ||
| 12.05. | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.04. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.03. | Zeo ScientifiX, Inc. - 10-Q, Quarterly Report | 6 | SEC Filings | ||
| 18.02. | Zeo ScientifiX, Inc.: ZEO ScientifiX Strengthens Leadership Team With The Appointment of Dr. Peter Everts as Chief Scientific and Technology Officer | 303 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / February 18, 2025 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company focused on the research and development... ► Artikel lesen | |
| 18.02. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.02. | ZEO ScientifiX, Inc.: ZEO ScientifiX Provides Business Update to Stockholders and the Investment Community | 272 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / February 11, 2025 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company focused on the research and development... ► Artikel lesen | |
| 10.02. | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.01. | Zeo ScientifiX, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 13.11.24 | ZEO ScientifiX, Inc.: ZEO ScientifiX and Exotropin Join Forces to Launch a Solution to Address the Growing Unmet Need for Hair Loss | 278 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESSWIRE / November 13, 2024 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a South Florida-based clinical-stage biopharmaceutical company, announced it has partnered... ► Artikel lesen | |
| 15.10.24 | Zeo ScientifiX, Inc.: ZEO ScientifiX, a Leading South Florida Biotechnology Company, Launches Regenerative Medicine Educational Series for Physicians | 230 | ACCESS Newswire | Events Hosted By ZEO ScientifiX Offer Providers Practical Business Tools Along With Science And Research Insights FORT LAUDERDALE, FL / ACCESSWIRE / October 15, 2024 / ZEO ScientifiX, Inc. ("ZEO" or... ► Artikel lesen | |
| 01.10.24 | Zeo ScientifiX, Inc.: ZEO ScientifiX Partners with National Provider of Healthcare Services | 242 | ACCESS Newswire | Physicians Group, LLC's Network Of Clinics And Diverse Patient Population Will Provide ZEO With Exclusive Research-Based OpportunitiesFORT LAUDERDALE, FL / ACCESSWIRE / October 1, 2024 / ZEO ScientifiX... ► Artikel lesen | |
| 24.09.24 | Zeo ScientifiX, Inc.: ZEO ScientifiX is Moving Toward Its Goal of Transforming Healthcare Through Leading-Edge Research | 308 | ACCESS Newswire | South Florida Biotech Company Seeks To Expand Its Research Program Into Phase 2 Clinical TrialsFORT LAUDERDALE, FL / ACCESSWIRE / September 24, 2024 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX)... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,200 | -16,85 % | Evotec, Hugo Boss, Lanxess, Nagarro, SMA Solar, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| QIAGEN | 41,050 | -0,86 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,380 | 0,00 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
| ITEOS THERAPEUTICS | 10,135 | 0,00 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
| BIONTECH | 93,05 | -1,69 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 55,50 | -0,89 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
| AVIDITY BIOSCIENCES | 34,040 | +0,89 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,340 | +0,53 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
| SAB BIOTHERAPEUTICS | 2,655 | 0,00 % | SAB Biotherapeutics sichert sich 175 Mio. US-Dollar über Privatplatzierung - Aktie legt um 33 % zu | ||
| REDHILL BIOPHARMA | 2,380 | 0,00 % | RedHill Biopharma Ltd.: RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease | The positive FDA feedback allows for:
A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium... ► Artikel lesen | |
| 180 LIFE SCIENCES | 2,800 | 0,00 % | 180 Life Sciences beschleunigt Zuteilung von Aktienvergütungen für Führungskräfte | ||
| ABSCI | 3,505 | 0,00 % | Absci Corporation: Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease | Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,130 | +2,39 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 35,210 | +0,11 % | Truist Securities initiates Harmony Biosciences stock with Buy rating |
ZEO SCIENTIFIX INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZEO SCIENTIFIX INC finden Sie auf Wallstreet Online.